Company Performance - Hongbo Pharmaceutical's stock price reached a historical high, increasing by 9.48% to 45.15 yuan, with a trading volume of 11.64 million shares and a transaction value of 520 million yuan, resulting in a turnover rate of 9.27% [2] - The company's latest A-share total market capitalization is 6.302 billion yuan, and the A-share circulating market capitalization is 5.672 billion yuan [2] - For the first three quarters, the company achieved an operating income of 514 million yuan, representing a year-on-year growth of 31.43%, and a net profit of 34.7496 million yuan, with a year-on-year increase of 127.96% [2] Industry Overview - The pharmaceutical and biotechnology industry overall saw a slight increase of 0.12%, with 198 stocks rising and 3 stocks hitting the daily limit, including Di'an Diagnostics and Meian Health [2] - Conversely, 276 stocks experienced declines, with the largest drops recorded by Haishike, Sansheng Guojian, and Yinuosi, with declines of 6.41%, 4.22%, and 4.20% respectively [2] Financing Data - As of January 9, the latest margin trading balance for Hongbo Pharmaceutical was 232 million yuan, with a financing balance of 232 million yuan, reflecting an increase of 18.6192 million yuan over the past 10 days, which is a growth of 8.74% [2]
泓博医药股价创新高，融资客抢先加仓